Cardiac toxicity associated with breast cancer treatment

Cardiotoxicity associated with breast cancer treatment refers to the adverse effect on the heart as a result of the treatment of breast cancer through chemotherapy, decomposition, target treatment, etc. First, there is a potential for cardiac toxicity of some chemotherapy drugs that may cause cardiac toxicity. For example, cystals (accumin, table acin, etc.) are among the chemotherapy drugs commonly used for breast cancer, but they can cause heart toxicity. The mechanism by which its heart toxicity occurs may be related to the free-base-to-heart cell damage of the drug, the metabolic and functional inhibition of myocardial cells, etc. Violines-type drugs (vigiol, Dositas, etc.) may also cause cardiac toxicity in some cases, although the incidence is relatively low. Target therapy for HeR2 target drugs such as trato-joy alone plays an important role in treating HeR2 positive breast cancer, but may also cause heart toxicity. The mechanism of heart toxicity may be associated with inhibiting the protection of the heart cell by the HeR2 signal circuit. The risk of cardiac toxicity is likely to increase, especially when used in combination with rim-type drugs. In the case of breast cancer treatment, there may be indirect effects on the heart. Treatment can lead to inflammation and fibrosis of the tissue around the heart and can affect the structure and functioning of the heart in the long term. In particular, patients with left-hand breast cancer receive relatively high doses of radiation in the heart and are at greater risk of heart toxicity. II. The impairment of myocardial myocardial function in clinical cardiac toxicity is reflected in a decrease in left cardiocardiology (LVEF). Patients may not have visible symptoms at an early stage, but LVEF can be found to be decreasing through a heart ultrasound examination. Symptoms of heart failure, such as respiratory difficulties, inactivity, edema, etc., may occur as the condition progresses. Anomalous myocardial enzyme spectroscopy, such as CK, CK-MB, CTn, and so forth, prompting loss of myocardial cell. Cardiopathic disorders can occur in various types, such as cardiac hyperactivity, cardiac hyperactivity, room early paces, room early paces, cardiac tremors, etc. Patients may feel discomfort, panic, breast discomfort, etc. Serious cardiac disorders, such as hypervelocity of the room, tremors of the heart can endanger life. Treatments such as the treatment of cardiac disease may lead to CPR or CPR. Patients can suffer from chest pains, respiratory difficulties, heart attacks, etc. Heart filling symptoms, such as low blood pressure, cardiac vilification, etc., can be pressured when the volume of the condensed fluid is high. III. Pre-treatment assessments for the monitoring and assessment of cardiac toxicity should provide a comprehensive heart assessment of patients, including medical history collection, medical examination, electrocardiograms, heart ultrasound, etc., before breast cancer treatment begins. Knowledge of the basic heart condition of the patient and assessment of risk factors for heart toxicity, such as age, past heart history, hypertension, diabetes, etc. Cardiac monitoring should be carried out on a regular basis for patients treated with drugs that may cause heart toxicity during treatment. For example, LVEF changes can be monitored every three months during the treatment of LVEFs and HER2 targets. At the same time, myocardial enzymes, electrocardiograms, etc. are regularly checked for early detection of cardiac toxicity. After treatment followed by breast cancer treatment, patients are still required to undergo long-term heart follow-up. Examinations of cardiac ultrasound, electrocardiograms, etc. are carried out on a regular basis to monitor changes in heart function, depending on the patient ‘ s circumstances. Patients with cardiac toxicity should be treated and followed up according to their condition. IV. Optimizing treatment programmes for preventive and curative measures of heart toxicity: To the extent possible, and subject to the assurance of the efficacy of the treatment, treatments with less heart toxicity are selected. For example, in the case of HeR2 positive breast cancer patients, the risk of cardiac toxicity may be reduced by using a relatively low heart toxicity HeR2 target or a sequenced treatment. Limiting drug doses: For drugs with a specific heart toxicity, such as thorium rims, the dose should be strictly controlled to avoid overdose. The individualisation of the dose is based on the patient ‘ s surface size, age, heart function, etc. The use of heart protection drugs: heart protection drugs, such as right Rezos, can be used at the same time when treated with drugs that may cause heart toxicity. Right Rezhossen can reduce the production of free radicals by combining with the rim-type drugs, thereby reducing cardiac toxicity. The treatment shall be proportional to the seriousness of the condition of the patient who has shown cardiac toxicity. Impairment of myocardial function: If LVEF drops but does not show obvious heart failure symptoms, the treatment of a drug with cardiac toxicity can be suspended, heart-protective drugs given and treatment supported, such as an accelerants (ACEI), vascular stressor receptors (ARB), beta receptor retardants, etc. These drugs improve myocardial reorganisation and protect the function of the heart. If LVEF falls seriously or suffers from heart failure, treatment shall be based on the principle of treatment for heart failure, including urea, strong heart, vascular drugs, etc. Cardiopathic disorders: Based on the type and severity of cardiac disorders, appropriate treatments are selected. For mild heart disorders, anti-cardiological disorders can be observed or used. The treatment of severe heart disorders, such as hypercardial hypervelocity, CPR, etc., may require electro-defibrillation or pacemaker implants. Cardiopathic diseases: Cardiocarditis or cardiac enzyme can be treated with anti-inflammatory drugs, urinants, etc. If the condensed volume of the heart is large, the pressure on the heart leads to heart filling symptoms, which may require the introduction of a convulsive flow.